donepezil has been researched along with Psychotic Disorders in 14 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications." | 9.12 | Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2006) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 9.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 8.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| " We investigated whether early and long-term use of donepezil prevents psychosis in non-demented PD patients." | 6.87 | Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years. ( Fujimura, H; Fukuda, T; Goto, M; Hasegawa, K; Ito, S; Kawamura, T; Kikuchi, S; Kiyohara, K; Kohsaka, M; Matsuo, H; Mizoguchi, K; Nakamura, M; Oeda, T; Park, K; Sawada, H; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K, 2018) |
| "Donepezil was safe and well-tolerated but was not effective compared with placebo as a cotreatment for the improvement of cognitive impairment in this patient population." | 6.73 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. ( Buchanan, RW; Goldman, R; Kane, JM; Keefe, RS; Li, C; Malhotra, AK; Meltzer, HY; Murthy, A; Sovel, M, 2008) |
| "Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications." | 5.12 | Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2006) |
| "Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen." | 5.12 | Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. ( DeVane, CL; Horner, MD; Markowitz, JS; McGurk, SR; Nahas, Z; Palecko, S; Risch, SC, 2007) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 4.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| " Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation." | 4.93 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. ( Barrantes, FJ; Peralta, MC; Perez-Lloret, S, 2016) |
| " We investigated whether early and long-term use of donepezil prevents psychosis in non-demented PD patients." | 2.87 | Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years. ( Fujimura, H; Fukuda, T; Goto, M; Hasegawa, K; Ito, S; Kawamura, T; Kikuchi, S; Kiyohara, K; Kohsaka, M; Matsuo, H; Mizoguchi, K; Nakamura, M; Oeda, T; Park, K; Sawada, H; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K, 2018) |
| " An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit." | 2.73 | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. ( Cummings, J; Kurlan, R; Raman, R; Thal, L, 2007) |
| "Donepezil was safe and well-tolerated but was not effective compared with placebo as a cotreatment for the improvement of cognitive impairment in this patient population." | 2.73 | Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. ( Buchanan, RW; Goldman, R; Kane, JM; Keefe, RS; Li, C; Malhotra, AK; Meltzer, HY; Murthy, A; Sovel, M, 2008) |
| "Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients." | 2.70 | Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. ( Bharucha, A; Chew, ML; Huber, KA; Jacob, NJ; Kastango, KB; Marin, R; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J; Sweet, RA, 2002) |
| "Ten patients with schizophrenia or schizoaffective disorder who received stable doses of antipsychotics and met DSM-IV criteria for TD were treated with donepezil, 5 to 10 mg/day, for 6 weeks after a 2-week baseline period." | 1.31 | Treatment of tardive dyskinesia with donepezil: a pilot study. ( Campbell, EC; Caroff, SN; Gallop, R; Havey, J; Mann, SC; Sullivan, KA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sawada, H | 1 |
| Oeda, T | 1 |
| Kohsaka, M | 1 |
| Umemura, A | 1 |
| Tomita, S | 1 |
| Park, K | 1 |
| Mizoguchi, K | 1 |
| Matsuo, H | 1 |
| Hasegawa, K | 1 |
| Fujimura, H | 1 |
| Sugiyama, H | 1 |
| Nakamura, M | 1 |
| Kikuchi, S | 1 |
| Yamamoto, K | 1 |
| Fukuda, T | 1 |
| Ito, S | 1 |
| Goto, M | 1 |
| Kiyohara, K | 1 |
| Kawamura, T | 1 |
| Cummings, J | 2 |
| Lai, TJ | 1 |
| Hemrungrojn, S | 1 |
| Mohandas, E | 1 |
| Yun Kim, S | 1 |
| Nair, G | 1 |
| Dash, A | 1 |
| Veronese, N | 1 |
| Solmi, M | 1 |
| Luchini, C | 1 |
| Lu, RB | 1 |
| Stubbs, B | 1 |
| Zaninotto, L | 1 |
| Correll, CU | 1 |
| Perez-Lloret, S | 1 |
| Peralta, MC | 1 |
| Barrantes, FJ | 1 |
| Singh, J | 1 |
| Kour, K | 1 |
| Jayaram, MB | 1 |
| Risch, SC | 3 |
| Horner, MD | 3 |
| McGurk, SR | 2 |
| Palecko, S | 2 |
| Markowitz, JS | 3 |
| Nahas, Z | 3 |
| DeVane, CL | 3 |
| Kurlan, R | 1 |
| Raman, R | 1 |
| Thal, L | 1 |
| Keefe, RS | 1 |
| Malhotra, AK | 1 |
| Meltzer, HY | 1 |
| Kane, JM | 1 |
| Buchanan, RW | 1 |
| Murthy, A | 1 |
| Sovel, M | 1 |
| Li, C | 1 |
| Goldman, R | 1 |
| Fergusson, E | 1 |
| Howard, R | 1 |
| Caroff, SN | 2 |
| Campbell, EC | 2 |
| Havey, JC | 1 |
| Sullivan, KA | 2 |
| Katz, IR | 1 |
| Mann, SC | 2 |
| McGurk, S | 1 |
| Owens, SD | 1 |
| Molloy, M | 1 |
| Gilliard, C | 1 |
| Christie, S | 1 |
| Mintzer, J | 1 |
| George, MS | 1 |
| Havey, J | 1 |
| Gallop, R | 1 |
| Pollock, BG | 1 |
| Mulsant, BH | 1 |
| Rosen, J | 1 |
| Sweet, RA | 1 |
| Mazumdar, S | 1 |
| Bharucha, A | 1 |
| Marin, R | 1 |
| Jacob, NJ | 1 |
| Huber, KA | 1 |
| Kastango, KB | 1 |
| Chew, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Tardive Dyskinesia With Galantamine[NCT00164242] | Phase 4 | 36 participants | Interventional | 2002-01-31 | Completed | ||
| Continuation Pharmacotherapy for Agitation of Dementia[NCT00073658] | Phase 2 | 137 participants | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for donepezil and Psychotic Disorders
| Article | Year |
|---|---|
Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Lewy Body Disease; Piperidi | 2016 |
Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2016 |
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.
Topics: Animals; Cholinergic Agents; Cholinergic Neurons; Clinical Trials as Topic; Cognition Disorders; Dem | 2016 |
Acetylcholinesterase inhibitors for schizophrenia.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarba | 2012 |
7 trials available for donepezil and Psychotic Disorders
| Article | Year |
|---|---|
Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepe | 2018 |
Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Affect; Analysis of Variance; Cross-Over Studies; Donepezil; Double-Blind Method; Female; Hum | 2006 |
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Clozapine; Cross-Over Studi | 2007 |
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Antips | 2007 |
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Double-B | 2008 |
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.
Topics: Adult; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Cognition Disorders; Cross-Over Studies | 2001 |
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; Donepezil; | 2002 |
3 other studies available for donepezil and Psychotic Disorders
| Article | Year |
|---|---|
Donepezil for the treatment of psychosis in dementia with Lewy bodies.
Topics: Aged; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Lewy Body Disease; Male; Piperid | 2000 |
Treatment of tardive dyskinesia with donepezil.
Topics: Adult; Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedul | 2001 |
Treatment of tardive dyskinesia with donepezil: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Donepezil; Dose-Response Relationship, Drug; Drug Administration | 2001 |